Baseline levels of soluble VEGF-A and sVEGFR2 were associated with poor survival outcomes in treatment-naive and pretreated advanced ccRCC patients receiving nivolumab in the BIONIKK and NIVOREN trials, respectively [72, 76] (Table 3). Here, VEGFA is linked to nonpapillary renal cell carcinoma.